The Fort Worth Press - Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

USD -
AED 3.672504
AFN 62.000368
ALL 81.399019
AMD 371.778334
ANG 1.789884
AOA 918.000367
ARS 1390.462956
AUD 1.401542
AWG 1.8
AZN 1.70397
BAM 1.67081
BBD 2.010834
BDT 122.673182
BGN 1.668102
BHD 0.377223
BIF 2969.673704
BMD 1
BND 1.275325
BOB 6.908482
BRL 4.980604
BSD 0.998337
BTN 94.041373
BWP 13.522713
BYN 2.828151
BYR 19600
BZD 2.007933
CAD 1.36795
CDF 2315.000362
CHF 0.787151
CLF 0.022781
CLP 896.609085
CNY 6.836304
CNH 6.83428
COP 3564.14
CRC 454.339945
CUC 1
CUP 26.5
CVE 94.37504
CZK 20.777504
DJF 177.786308
DKK 6.375104
DOP 59.475368
DZD 132.362551
EGP 52.572403
ERN 15
ETB 154.33875
EUR 0.85304
FJD 2.20465
FKP 0.741029
GBP 0.740988
GEL 2.680391
GGP 0.741029
GHS 11.103856
GIP 0.741029
GMD 73.503851
GNF 8763.489017
GTQ 7.643154
GYD 209.167133
HKD 7.83545
HNL 26.529324
HRK 6.429504
HTG 130.705907
HUF 311.520388
IDR 17252.7
ILS 2.98605
IMP 0.741029
INR 94.250504
IQD 1307.826829
IRR 1317000.000352
ISK 122.650386
JEP 0.741029
JMD 157.551717
JOD 0.70904
JPY 159.36504
KES 129.330385
KGS 87.403204
KHR 4000.00035
KMF 420.00035
KPW 900.025942
KRW 1476.640383
KWD 0.30776
KYD 0.83199
KZT 463.757731
LAK 21876.732779
LBP 89402.943058
LKR 318.234165
LRD 183.194711
LSL 16.601322
LTL 2.95274
LVL 0.60489
LYD 6.334826
MAD 9.25038
MDL 17.361484
MGA 4148.432502
MKD 52.578375
MMK 2099.863185
MNT 3580.436774
MOP 8.056729
MRU 39.846449
MUR 46.870378
MVR 15.450378
MWK 1731.200682
MXN 17.379604
MYR 3.965039
MZN 63.910377
NAD 16.601322
NGN 1357.000344
NIO 36.741309
NOK 9.317039
NPR 150.466197
NZD 1.706339
OMR 0.38415
PAB 0.999748
PEN 3.487039
PGK 4.333547
PHP 60.695038
PKR 278.317253
PLN 3.61995
PYG 6330.560887
QAR 3.645504
RON 4.340504
RSD 100.166347
RUB 75.185839
RWF 1459.245042
SAR 3.751023
SBD 8.045307
SCR 14.798038
SDG 600.503676
SEK 9.22035
SGD 1.276104
SHP 0.746601
SLE 24.625038
SLL 20969.496166
SOS 570.526765
SRD 37.463504
STD 20697.981008
STN 20.899979
SVC 8.735338
SYP 110.562389
SZL 16.594583
THB 32.335038
TJS 9.384602
TMT 3.505
TND 2.881038
TOP 2.40776
TRY 45.015038
TTD 6.780124
TWD 31.483504
TZS 2598.251226
UAH 43.992664
UGX 3719.475993
UYU 39.60396
UZS 12052.503617
VES 483.16466
VND 26360
VUV 117.829836
WST 2.712269
XAF 559.570911
XAG 0.013194
XAU 0.000212
XCD 2.70255
XCG 1.799275
XDR 0.695927
XOF 559.570911
XPF 102.250363
YER 238.650363
ZAR 16.53436
ZMK 9001.203584
ZMW 18.893581
ZWL 321.999592
  • BCC

    0.3300

    84.15

    +0.39%

  • CMSD

    0.0900

    23.32

    +0.39%

  • JRI

    0.0100

    12.89

    +0.08%

  • RBGPF

    64.0000

    64

    +100%

  • NGG

    0.4600

    87.42

    +0.53%

  • BCE

    -0.2200

    23.88

    -0.92%

  • CMSC

    0.0400

    22.95

    +0.17%

  • RYCEF

    -0.1200

    15.3

    -0.78%

  • VOD

    0.0100

    15.63

    +0.06%

  • RELX

    0.4000

    36.53

    +1.09%

  • GSK

    -1.1900

    54.44

    -2.19%

  • AZN

    -2.5500

    189.75

    -1.34%

  • BTI

    0.8100

    58.09

    +1.39%

  • BP

    -0.1000

    46.25

    -0.22%

  • RIO

    0.7600

    99.61

    +0.76%

Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22
Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22

ORLANDO, FLORIDA / ACCESS Newswire / October 2, 2025 / RedChip Companies will host an investor webinar with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)(NASDAQ:SXTPW), a pharmaceutical company focused on developing new medicines for vector-borne diseases, on October 22, 2025, at 4:15 p.m. ET. The event will feature 60 Degrees Pharmaceuticals' CEO Geoffrey Dow, PhD.

Text size:

Dr. Dow will highlight the potential of ARAKODA® (tafenoquine), an FDA-approved antimalarial developed with the U.S. Army, and its expanding commercial footprint in the U.S. He will also outline the company's plan to expand FDA approval for tafenoquine to babesiosis-a growing tick-borne illness, incidence of which, management believes is vastly underrepresented by CDC estimates and for which there is no FDA-approved therapy. 60 Degrees Pharmaceuticals has two clinical trials (hospitalized babesiosis patients and relapsing patients) underway, and initiation of a third planned near-term.

60 Degrees Pharmaceuticals has Orphan Drug status for tafenoquine for babesiosis and patent exclusivity for the malaria indication through 2035.

A live Q&A session with management will follow the presentation.

To register for the free webinar, please visit: https://www.redchip.com/webinar/SXTP/88177419350

Questions can be pre-submitted to [email protected] or online during the live event.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of vector-borne diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of War and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

Follow RedChip on Twitter: https://twitter.com/RedChip

Follow RedChip on YouTube: https://www.youtube.com/@redchip

Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-REDCHIP (733-2447)
[email protected]

--END--

SOURCE: RedChip Companies, Inc.



View the original press release on ACCESS Newswire

T.Gilbert--TFWP